Abstract Library

#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma

Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liu D

Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,

Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,

#2910 Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers

Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Lauer U

Authors: Lauer U, Berchtold S, Smirnow I, Schaller M, Fehrenbacher B,

Keywords: neuroendocrine, cancer, virotherapy, virotherapeutics, preclinical, research,

#2810 Development of a Personalized Human Immunocompetent Ex-Vivo Model of Neuroendocrine Liver Metastasis Using Precision Cut Tissue Slice Technology

Introduction: Liver metastasis (LM) are very frequent (65-95%) and represent a crucial prognostic factor in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP NENs). The paucity of relevant experimental models has limited the understanding of the pathophysiology of NENs and the development of efficient therapeutic strategies

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Doornebal E

Authors: Doornebal E, Harris N, Miquel R, Zen Y, Pizanias M,

Keywords: Liver, neuroendocrine liver metastasis, ex-vivo model, personalized medicine, immunocompetent, organotypic tissue slices,

#2804 Claudin-18 Is a Sensitive and a Specific Marker for Gastric Neuroendocrine Tumors

Introduction: Antibody-based cancer therapies are emerging as promising therapeutics in oncology, including one in clinical trials that targets claudin-18, a protein expressed in normal gastric epithelium and some gastric adenocarcinoma. We currently have no markers for gastric well-differentiated neuroendocrine tumors (NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wong M, Huynh C, Kim S, Dhall D, Guindi M,

Keywords: claudin-18, anti-claudin 18, neuroendocrine tumor, neuroendocrine hyperplasia, autoimmune metaplastic atrophic gastritis,

#2692 Development of Ex-Vivo Models of Metastatic Neuroendocrine Neoplasms

Introduction: The lack of relevant in-vivo and in-vitro models has precluded investigations of the pathophysiology of metastatic NENs. Organotypic tumour slices retain the complexity of tumours in-vivo without extensive manipulation of the tissue.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Srirajaskanthan R

Authors: Srirajaskanthan R, Doornebal E, Harris N, Zen Y, Pizanias M,

Keywords: ex-vivo, organotypic tumour slices, immune environment, models,